for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Phathom Pharmaceuticals Inc

PHAT.OQ

Latest Trade

45.86USD

Change

0.00(0.00%)

Volume

21,330

Today's Range

45.82

 - 

46.65

52 Week Range

22.06

 - 

63.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
45.86
Open
45.93
Volume
21,330
3M AVG Volume
3.02
Today's High
46.65
Today's Low
45.82
52 Week High
63.94
52 Week Low
22.06
Shares Out (MIL)
28.96
Market Cap (MIL)
1,440.55
Forward P/E
-13.55
Dividend (Yield %)
--

Next Event

Phathom Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Phathom Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Phathom Pharmaceuticals Announces Proposed Public Offering Of 2,250,000 Shares Of Common Stock

Phathom Pharmaceuticals Announces Completion Of Patient Enrollment In Phase 3 Erosive Esophagitis Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing treatments for gastrointestinal (GI) diseases. Its product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker (P-CAB). It is developing vonoprazan as an agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. Vonoprazan accumulates in the secretory canaliculus where the proton pumps are present in their active state. Vonoprazan binds to proton pumps in both their inactive and active states and remains in the secretory canaliculus where it continues to inhibit acid secretion over an extended period.

Industry

Biotechnology & Drugs

Contact Info

100 CAMPUS DRIVE,, SUITE 102

FLORHAM PARK, NJ

07932

United States

+1.302.6365400

https://www.phathompharma.com/

Executive Leadership

Tadataka Yamada

Independent Chairman of the Board

Terrie J. Curran

President, Chief Executive Officer, Director

David Socks

Co-Founder, Chief Financial Officer, Treasurer, Director

Azmi Nabulsi

Co-Founder, Chief Operating Officer

Aditya Kohli

Chief Business Officer and Co-founder

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-22.450

2020(E)

-3.407
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
7.65
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
29.81
LT Debt To Equity (MRQ)
26.26
Return on Investment (TTM)
-459.63
Return on Equity (TTM)
-111.63

Latest News

Latest News

BRIEF-Phathom Pharmaceuticals Provides Clinical Trial Status Update

* PHATHOM PHARMACEUTICALS PROVIDES CLINICAL TRIAL STATUS UPDATE

BRIEF-Phathom Pharma On May 5, Entered Into A Commercial Supply Agreement With Takeda Pharmaceutical Company Limited

* PHATHOM PHARMACEUTICALS INC - ON MAY 5, ENTERED INTO A COMMERCIAL SUPPLY AGREEMENT WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED

BRIEF-Phathom Pharma Pauses New Patient Randomization In Trials Due To Coronavirus

* PHATHOM REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CLINICAL TRIAL STATUS AND BUSINESS UPDATES

BRIEF-Medicxi Growth I GP Limited Reports 8.4% Passive Stake In Phathom Pharmaceuticals As Of Dec 31, 2019 - SEC Filing

* MEDICXI GROWTH I GP LIMITED REPORTS 8.4% PASSIVE STAKE IN PHATHOM PHARMACEUTICALS AS OF DEC 31, 2019 - SEC FILING Source text: (http://bit.ly/2UGyxaM) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up